Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Outlook Therapeutics (OTLK) Receivables - Net (2016 - 2025)

Outlook Therapeutics has reported Receivables - Net over the past 3 years, most recently at $114609.0 for Q4 2025.

  • Quarterly Receivables - Net changed N/A to $114609.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114609.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, N/A changed from the prior year.
  • Receivables - Net was $114609.0 for Q4 2025 at Outlook Therapeutics, down from $1.5 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $1.8 million in Q2 2025 and troughed at $114609.0 in Q4 2025.